We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets ... Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Show more
WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (โPortageโ or the โCompanyโ) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel...
No impact at this time on the listing of the Companyโs Ordinary Shares on NasdaqCompany intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.85 | -42.5884955752 | 9.04 | 12.89 | 5.19 | 7545898 | 8.96911227 | CS |
4 | 0.56 | 12.0950323974 | 4.63 | 12.89 | 2.95 | 2002431 | 8.92687967 | CS |
12 | -1.46 | -21.954887218 | 6.65 | 12.89 | 2.95 | 686112 | 8.75185204 | CS |
26 | 0.448 | 9.44749051033 | 4.742 | 23.01 | 2.098 | 1528538 | 7.03199318 | CS |
52 | -25.61 | -83.1493506494 | 30.8 | 40.8 | 2.098 | 879141 | 7.10110894 | CS |
156 | -246.81 | -97.9404761905 | 252 | 252.014 | 2.098 | 310720 | 12.84980603 | CS |
260 | -744.81 | -99.308 | 750 | 899.526 | 2.098 | 250413 | 26.86791507 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions